CNS Pharmaceuticals, Inc. (CNSP)
| Market Cap | 2.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.56M |
| Shares Out | 1.33M |
| EPS (ttm) | -10.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,471 |
| Open | 2.31 |
| Previous Close | 2.35 |
| Day's Range | 2.12 - 2.43 |
| 52-Week Range | 2.05 - 16.50 |
| Beta | 1.18 |
| Analysts | Sell |
| Price Target | 10.20 (+372.22%) |
| Earnings Date | Mar 2, 2023 |
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceu... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CNSP stock is "Sell." The 12-month stock price forecast is $10.2, which is an increase of 372.22% from the latest price.
News
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Enrollment continuing to progress toward an interim analysis, planned when 30-50% of subjects reach the primary endpoint expected mid-year 2023 HOUSTON , Feb. 7, 2023 /PRNewswire/ -- CNS Pharmaceutic...
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland
Study to evaluate Berubicin for the treatment of newly diagnosed and relapsed/refractory primary central nervous system lymphoma (PCNSL) or non-Hodgkin's lymphoma with central nervous system involveme...
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18 th at 10:00 AM ET HOUSTON , January 5, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations HOUSTON , Jan. 3, 2023 /PRNewswi...
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Data recently presented at the Society for Neuro-Oncology (SNO) 27th Annual Meeting Preliminary results showcase updated patient population profile and safety Continued progress toward planned interim...
CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event
Live moderated video webcast event intended to provide the investment community direct access to ask their questions to John Climaco, Chief Executive Officer on Tuesday, December 6 th at 11:00 AM ET H...
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
HOUSTON , Nov. 30, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a...
CNS Pharmaceuticals Announces Reverse Stock Split
HOUSTON , Nov. 28, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary ...
CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Significant progress advancing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM) Quarter marked by expansion into Europe with multiple clinica...
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Enrollment progressing toward interim analysis, planned when 30-50% of subjects reach 6 months in study HOUSTON , Nov. 2, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "C...
CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run
HOUSTON , Oct. 10, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary ...
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for p...
CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Sites in France and Spain now open and actively enrolling Enrollment progressing with 26 clinical trial sites open to-date of the 59 sitesselected across the U.S., Italy, France, Spain, and Switzerlan...
CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM)
Live moderated video webcast with Management to discuss potentially pivotal global study of lead asset, Berubicin, on Wednesday, September 28 th at 1:00 PM ET HOUSTON , Sept. 23, 2022 /PRNewswire/ -- ...
CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON , Sept. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary ...
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Continued execution on clinical operations for potentially pivotal global trial evaluating Berubicin for the treatment of Glioblastoma Multiforme ("GBM") Enrollment progressing with 23 clinical tria...
CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022
Company reiterates support of proposals for the authorization to increase number of shares available for issuance by the Company and authorization for the Board to effect a reverse stock split at thei...
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Expanded eligibility for patients who have received multiple therapies as first line therapy for GBM Company continues to enroll patients for the trial with 19 clinical trial sites open to-date, and a...
CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
HOUSTON , June 8, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary an...
CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference
HOUSTON , May 24, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a...
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
HOUSTON , May 18, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary an...
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Recent approvals of potentially pivotal Berubicin Study into Switzerland, France, and Spain expected to significantly drive patient enrollment Opportunities for Berubicin to be used in additional onco...
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Continued advancement of global patient enrollment with Switzerland, France, and Spain approvals received for pivotal study of Berubicin HOUSTON , April 28, 2022 /PRNewswire/ -- CNS Pharmaceuticals, I...
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications an...
CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event
Live video webcast with moderated fireside chat with members from the CNS Pharmaceuticals management team and featuring Key Opinion Leader, Samuel A. Goldlust, MD, on Thursday, April 14th at 11:30 AM ...